Publications by authors named "Machiko Irie"

Claim this Profile
S
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display.
Mirai Kage, Ryuji Hayashi, Atsushi Matsuo, Minoru Tamiya, Shino Kuramoto, Machiko Irie

Bioorg Med Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.
Yuu Okura, Yuri Ikawa-Teranishi, Akihiko Mizoroki, Noriyuki Takahashi, Takashi Tsushima, Machiko Irie

Nat Commun· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets.
Atsushi Ohta, Mikimasa Tanada, Shojiro Shinohara, Yuya Morita, Kazuhiko Nakano, Machiko Irie

J Am Chem Soc· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor.
Mikimasa Tanada, Minoru Tamiya, Atsushi Matsuo, Aya Chiyoda, Koji Takano, Machiko Irie

J Am Chem Soc· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.
Taku Fukuzawa, Zenjiro Sampei, Kenta Haraya, Yoshinao Ruike, Meiri Shida-Kawazoe, Machiko Irie

Sci Rep· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD).
Terushige Muraoka, Mitsuaki Ide, Machiko Irie, Kenji Morikami, Takaaki Miura

Chem Pharm Bull (Tokyo)· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD).
Terushige Muraoka, Mitsuaki Ide, Kenji Morikami, Machiko Irie, Mitsuaki Nakamura

Bioorg Med Chem· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors.
Takashi Chiba, Jun Ohwada, Hiroshi Sakamoto, Takamitsu Kobayashi, Takaaki A Fukami, Machiko Irie

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structure of the halotolerant gamma-glutamyltranspeptidase from Bacillus subtilis in complex with glutamate reveals a unique architecture of the solvent-exposed catalytic pocket.
Kei Wada, Machiko Irie, Hideyuki Suzuki, Keiichi Fukuyama

FEBS J· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structures of Escherichia coli gamma-glutamyltranspeptidase in complex with azaserine and acivicin: novel mechanistic implication for inhibition by glutamine antagonists.
Kei Wada, Jun Hiratake, Machiko Irie, Toshihiro Okada, Chiaki Yamada

J Mol Biol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis